We have shown that our parametric model can be applied to aggressive as well as indolent clones of B-cell lymphomas, and that it can predict the efficacy of a combination of anti-Bcl-2 ABT-263, a predecessor drug to ABT-199, and anti-CD-20 rituximab in the absence of an immune system. The gene discussed is BCL2; the disease is B-cell non-Hodgkin lymphoma.